Literature DB >> 33704490

Positron emission tomography imaging of drug concentrations in the brain.

Patrick Y Wen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33704490      PMCID: PMC8041320          DOI: 10.1093/neuonc/noab025

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.

Authors:  Michael A Vogelbaum; Daria Krivosheya; Hamid Borghei-Razavi; Nader Sanai; Michael Weller; Wolfgang Wick; Riccardo Soffietti; David A Reardon; Manish K Aghi; Evanthia Galanis; Patrick Y Wen; Martin van den Bent; Susan Chang
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 2.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Authors:  Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon
Journal:  J Clin Oncol       Date:  2019-02-04       Impact factor: 44.544

Review 4.  The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.

Authors:  Mirjam Gerwing; Ken Herrmann; Anne Helfen; Christoph Schliemann; Wolfgang E Berdel; Michel Eisenblätter; Moritz Wildgruber
Journal:  Nat Rev Clin Oncol       Date:  2019-07       Impact factor: 66.675

5.  Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Authors:  Aurelija Jucaite; Per Stenkrona; Zsolt Cselényi; Serena De Vita; Nuria Buil-Bruna; Katarina Varnäs; Alicia Savage; Andrea Varrone; Peter Johnström; Magnus Schou; Chris Davison; Andy Sykes; Venkatesh Pilla Reddy; Matthias Hoch; Ana Vazquez-Romero; Mohammad Mahdi Moein; Christer Halldin; Melinda S Merchant; Martin Pass; Lars Farde
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

6.  A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Authors:  Andrew M Scott; Fook-Thean Lee; Niall Tebbutt; Rebecca Herbertson; Sanjeev S Gill; Zhanqi Liu; Effie Skrinos; Carmel Murone; Timothy H Saunder; Bridget Chappell; Anthony T Papenfuss; Aurora M T Poon; Wendie Hopkins; Fiona E Smyth; Duncan MacGregor; Lawrence M Cher; Achim A Jungbluth; Gerd Ritter; Martin W Brechbiel; Roger Murphy; Antony W Burgess; Eric W Hoffman; Terrance G Johns; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

Review 7.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Authors:  Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

8.  Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Authors:  Stuart A Grossman; Carlos G Romo; Michelle A Rudek; Jeffrey Supko; Joy Fisher; L Burt Nabors; Patrick Y Wen; David M Peereboom; Benjamin M Ellingson; William Elmquist; Fred G Barker; David Kamson; Jann N Sarkaria; William Timmer; Ranjit S Bindra; Xiaobu Ye
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

9.  Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.

Authors:  Jing Li; Jun Jiang; Jianmei Wu; Xun Bao; Nader Sanai
Journal:  Clin Pharmacol Ther       Date:  2020-09-14       Impact factor: 6.875

  9 in total
  2 in total

Review 1.  Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Authors:  Stephen J Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q Lee; Gavin P Dunn; Evanthia Galanis; Susan M Chang; Louis Burt Nabors; Manmeet S Ahluwalia; Roger Stupp; Minesh P Mehta; David A Reardon; Stuart A Grossman; Erik P Sulman; John H Sampson; Simon Khagi; Michael Weller; Timothy F Cloughesy; Patrick Y Wen; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

Review 2.  Advances in electrical impedance tomography-based brain imaging.

Authors:  Xi-Yang Ke; Wei Hou; Qi Huang; Xue Hou; Xue-Ying Bao; Wei-Xuan Kong; Cheng-Xiang Li; Yu-Qi Qiu; Si-Yi Hu; Li-Hua Dong
Journal:  Mil Med Res       Date:  2022-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.